Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial - Concepedia

Concepedia

Publication | Open Access

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

DOI Full Paper Access

108

Citations

19

References

2017

Year

Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke, Pierfranco Conté, Carlos L. Arteaga, David Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, J. Thaddeus Beck,

Breast Cancer Research and Treatment

Abstract

Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.

References

	Year	Citations

Page 1